Evidence map›Paper›PMID 39049905›Full record

ArticleAnnals of blood2024

The history of thrombotic thrombocytopenic purpura research: a narrative review.

Konstantine Halkidis, Bernhard Lämmle, X Long Zheng

Abstract read
In one paragraph

Article in Annals of blood, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Konstantine HalkidisDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Bernhard LämmleCenter for Thrombosis and Hemostasis, University Medical Center, Mainz, Germany.
X Long ZhengDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.

Funding

Pathogenesis of thrombotic microangiopathiesR01HL164016 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI X. Long Zheng · 2023 to 2026
$2.1M
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic PurpuraR01HL144552 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ZHENG, X. LONG · 2019 to 2022
$1.8M
Mechanism underlying cofactor-dependent proteolysis of von Willebrand FactorR01HL157975 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ZHANG, XIAOHUI FRANK, ZHENG, X. LONG · 2022 to 2025
$1.8M
Exploring the mechanisms of action of anti-ADAMTS 13 antibodies in immune thrombotic thrombocytopenic purpuraK08HL163471 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Konstantine Halkidis · 2022 to 2026
$826k
NHLBI NIH HHS K08 HL163471NHLBI NIH HHS R01 HL144552NHLBI NIH HHS R01 HL157975NHLBI NIH HHS R01 HL164016
6 · The paper itself

Abstract

Background and Objective: Thrombotic thrombocytopenic purpura (TTP) is a rare but debilitating thrombotic microangiopathy that results from severe deficiency of the enzyme ADAMTS13. The disorder was first described in the early 20 Methods: We searched literature using PubMed from 1924 to 2023 using the following free text searches: "thrombotic thrombocytopenic purpura", "Moschcowitz disease", and "thrombotic microangiopathy". We found 6,917 peer-reviewed articles and sorted through these for relevant literature pertinent to the review. A total of 46 articles were included for review and the remainder were excluded. Key Content and Findings: The history of TTP research was reviewed, with a sampling of major events in the evolution of the understanding of the pathophysiology and treatment of the disease discussed here. There remains much to be learned about the nature of the disease in order to develop more specific and less harmful treatments. Conclusions: An overview of the major discoveries that have led to our current understanding of TTP reveals the results of collaboration of multiple groups of physicians and scientists through the past century, with additional breakthroughs likely to occur in the future because of that same collaborative spirit.

Indexed as

therapeutic plasma exchangethrombotic microangiopathyThrombotic thrombocytopenic purpura (TTP)von Willebrand factor (VWF)

Identifiers

PMID39049905
PMCPMC11268837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.